Flex Pharma Reports Year End 2016 Financial Results

07:00 EST 8 Mar 2017 | Businesswire

This article has expired, however you can still download the PDF.
-- IND Submission for FLX-787 On Track for H1 2017 ---- Phase 2 ALS & CMT Studies with FLX-787 Planned to Initiate This Year ---- Successful Launch Year for HOTSHOT® Consumer Brand; Revenue Exceeds Expectations --Conference...

Other Sources for this Article

Flex Pharma, Inc.
Elizabeth Woo, 617-874-1829
SVP, Investor Relations & Corporate Communications


More From BioPortfolio on "Flex Pharma Reports Year End 2016 Financial Results"

Quick Search


Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Antibodies Antisense Assays Biochips Bioinformatics Biological Therapy Biomarkers Biomaterials Bioscience Cell Culture Cloning Cytokine Diagnostics Dna Extraction Dna Sequencing Dna Transform...

Multiple Sclerosis MS
Multiple sclerosis (MS) is the most common disabling neurological condition affecting 100,000 young adults in the UK. The condition results from autoimmune damage to myelin, causing interference in nerve signaling. Symptoms experienced depend on the pa...